



The first synthesis of spirocyclopentyl derivatives of lupane triterpenoids by radical nitrocyclization of C-2-diallyl substituted betulonates

Anna Yu. Spivak^{a,*}, Elvira R. Shakurova^a, Darya A. Nedopekina^a, Sergey L. Khursan^b,
Michail Yu. Ovchinnikov^b, Leonard M. Khalilov^a, Victor N. Odinokov^a

^a Institute of Petrochemistry and Catalysis, Russian Academy of Sciences, 141 Prospekt Oktyabrya, Ufa 450075, Russian Federation

^b Institute of Organic Chemistry, Ufa Research Center, Russian Academy of Sciences, 71 Prospekt Oktyabrya, Ufa 450054, Russian Federation

ARTICLE INFO

Article history:

Received 26 September 2011

Revised 24 October 2011

Accepted 4 November 2011

Available online 10 November 2011

Keywords:

Lupane triterpenoids

Betulonic acid

1,6-Hexadienes

Radical cyclization

Spirocycles

ABSTRACT

Radical cyclization of the 1,6-hexadiene moiety in 2,2-diallyl substituted methyl or benzyl dihydrobetulonates initiated by $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ in the presence of FeCl_3 or LiCl gave hitherto unknown spirocyclic compounds in which ring A of the lupane triterpenoid at position C-2 is spiro coupled with a vicinally substituted nitromethyl- and chloromethylcyclopentane. Based on a quantum-chemical assessment of the energy characteristics of this reaction, the most probable configurations of the chiral atoms in the spirocyclopentane ring were determined for the major diastereomers isolated in individual form.

© 2011 Elsevier Ltd. All rights reserved.

Pentacyclic triterpenoids of lupane series constitute an important class of bioactive compounds possessing a broad scope of activity. These compounds are of special interest due to their antitumor and antiviral properties.¹ Lupane triterpenoids manifest low toxicity against animals even in high concentrations, but the relatively weak potential of their biological effect hinders considerably the use of these compounds in clinical practice. In view of this, studies on the synthesis of betulin and betulonic acid derivatives by the modification of functional groups at C-3 and C-28 atoms have been under way in the past years. These studies resulted in a group of compounds that had superior antitumor and antiviral activities in comparison with native compounds.^{2,3} However, studies aimed at modifications of ring A in betulonic or betulonic acids^{1,3–5} are no less promising. We have recently developed a facile and efficient method for synthesizing 2,2-diallyl-substituted 3-ketolupanes **1** and **2** that are of interest as polyfunctional block-synthons for new derivatives of lupane triterpenoids with modified ring A.⁶ These compounds can be converted into potentially bioactive spirocyclic systems by cyclization of the 1,6-hexadiene moiety under conditions of radical^{7,8} or catalytic reactions on treatment with transition metal complexes,^{9,10} including olefin metathesis catalysts.¹¹

In this work, we have studied the radical cyclization of 2,2-diallyl-substituted methyl and benzyl dihydrobetulonates **1** and **2** initiated by $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ (under its thermal degradation conditions) in the presence of FeCl_3 or LiCl as radical traps. The reaction performed by short refluxing of the reagents in THF gave a mixture of diastereomeric compounds **3** and **4**, respectively, in good yields (Scheme 1).¹²

MALDI TOF mass spectra of a mixture of compounds **3** or **4** contained molecular ion peaks corresponding to their molecular formulas (for compound **3**, m/z 654.98 $[\text{M}+\text{Na}]^+$, 670.96 $[\text{M}+\text{K}]^+$; for compound **4**, 730.40 $[\text{M}+\text{Na}]^+$, 746.37 $[\text{M}+\text{K}]^+$).


¹H NMR spectra of cyclization products **3** and **4** contained signals of CH_2NO_2 and CH_2Cl moieties as broad multiplets that resonate at δ 4.30–4.75 and 3.45–3.65, respectively. In the ¹³C NMR spectra, these groups manifested themselves as characteristic methylene signals: δ 75.81 and 44.45 for compounds **3**; δ 75.83, and 44.46 for compounds **4**.

Analysis of NMR spectra of these compounds did not allow us to determine their stereoisomeric compositions. Major isomers **3a** and **4a** were isolated as individual compounds from hardly-separable diastereomeric mixtures of **3** and **4** using column chromatography on silica gel (Fig. 1). The structures of compounds **3a** and **4a** were partially confirmed by the analysis of one-dimensional ¹H and ¹³C NMR spectra, two-dimensional homo-(COSY, NOESY) and heteronuclear experiments (HSQC, HMBC).

The ¹H and ¹³C NMR spectra, with a slight difference in chemical shifts between compounds **3a** and **4a**, totally matched their

* Corresponding author. Tel.: +7 347 284 3544; fax: +7 347 284 2750.

E-mail addresses: s.spivak@bashnet.ru (A.Yu. Spivak), chemorg@anrb.ru (S.L. Khursan).



Scheme 1. Radical nitrocyclization of dihydrobetulonates **1** and **2**.




Figure 1. Diastereomeric spiro compounds **3a–d** with an *R*-configuration of the spiro atom.

structure; each spectrum contained a single set of characteristic signals of the lupane and cyclopentane moieties and those of the respective substituents. Their ^{13}C NMR spectra showed an upfield shift of the singlet signal of the quaternary C-2 carbon in ring A ($\Delta \delta$ 5.7 ppm) in comparison with its positions in the spectra of the original esters **1** and **2**. The coupling constant of vicinal protons HC- $\dot{3}$ (δ 2.7) and HC- $\dot{4}$ (δ 3.0) observed in ^1H NMR spectra, which amounted to 8 Hz, suggested a mutual *cis*-orientation of these protons and hence a *cis*-arrangement of the CH_2NO_2 and CH_2Cl groups in the spirocyclopentane moiety. The mutual *cis*-orientation of substituents was confirmed by intense cross peaks in the NOESY spectrum between the protons of CH_2Cl (δ 3.5) and CH_2NO_2 (δ 4.4).

However, NMR spectroscopy did not allow us to make an exhaustive conclusion about the stereochemical structure of the

spiro compounds. In order to obtain information about the absolute configuration of the chiral carbon atoms of the cyclopentane ring, we performed a theoretical analysis of the stereochemical features of the reaction in question.¹³

Using 2,2-diallyl substituted cyclohexanone **1'** (Fig. 2) as a model compound whose conformational structure matches the structure of ring A in the starting lupane terpenoids (**1**, **2**), we studied the mechanism of radical cyclization that occurs by Scheme 1 (cf. Ref. 7) by means of DFT and ab initio methods. *exo*-Cyclization of 1,6-hexadiene moiety in methyl dihydrobetulonate **1** (or model compound **1'**) to cyclopentane can result in eight diastereomers: four pairs of molecules with *cis*- and *trans*-arrangement of vicinal CH_2NO_2 and CH_2Cl groups that differ in arrangement of the latter with respect to the plane of ring A of the lupane frame (Figs. 1 and 3; only diastereomers **3a–d** and **3a'–d'** with an *R*-configuration of the spiro atom are shown).

Calculations of the full energies of optimized structures of all isomers of model compounds **3a'–d'** (Fig. 3) in B3LYP/6–31G(d) approximation suggest unambiguously that *trans*-isomers are energetically favorable: the energy difference between the least stable *trans*-isomer **3b'** and the most stable *cis*-isomer **3a'** (or reaction products **3b** and **3a**) amounted to 9 kJ/mol, while the energy




Figure 3. Diastereomeric model spiro compounds **3a'–d'** with an *R*-configuration of the spiro atom.





Figure 2. Conformational structure of model 2,2-diallyl substituted cyclohexanone **1'** and ring A in 2,2-diallyl substituted methyl betulonate **1** (both rings have the 'twist' conformation).



Scheme 2. Assumed mechanism of radical nitrocyclization of methyl betulonate **1**.

difference between the most stable *trans*-isomer **3c'** and isomer **3a'** (or reaction products **3c** and **3a**) is 15 kJ/mol (see Tables 1 and 2 in Supplementary data).

However, it follows from our experimental data that *cis*-isomers that are less stable thermodynamically are formed in major amounts. In fact, the yield of *cis*-isomer **3a** amounted to 60% of the diastereomer mixture **3**.¹² To explain this apparent contradiction, it was assumed that the selective formation of the *cis*-isomer, which is less stable thermodynamically, is determined by the kinetics and mechanism of the reaction in question. This hypothesis is supported by known facts¹⁴ about the preferential formation of *cis*-substituted cyclopentanes in the radical cyclization of 1,6-hexadienes.

According to the hypothetical mechanism suggested for radical nitrocyclization of 1,6-dienes,⁷ the reaction of C-2-diallyl substi-

tuted dihydrobetulonates, for example, methyl dihydrobetulonate **1**, starts with radical addition of nitrogen dioxide to one of the double bonds of the 1,6-diene moiety followed by 5-*exo*-cyclization of intermediate **5** to intermediate **6** that contains a cyclopentylmethyl group spiro coupled with ring A of the lupane triterpenoid. Radical intermediate **6** is trapped by the chlorine atom to give reaction product **3** (Scheme 2).

When selecting the theoretical method to study the assumed nitrocyclization mechanism of compound **1**, it was taken into account that the B3LYP hybrid functional overstates the contribution of the pathway that results in the *trans*-isomer in radical cyclization of substituted hexenyl radicals, which occurs in a manner similar to the reaction in question.¹⁴ It is recommended to use the HandHLYP (BHLYP) hybrid functional for this purpose and, if possible, verify the reliability of the calculation results using the com-




Figure 4. Radical cyclization mechanism for model compound, 2,2-diallylcyclohexanone **1'**, as an example. The relative Gibbs energies (kJ/mol) of the transition states calculated in the BHLYP/cc-pVTZ approximation with nonspecific solvation (tetrahydrofuran) taken into account are shown in parentheses.

posite method. Therefore, the B3LYP functional combined with the Dunning basis set with cc-pVTZ triple splitting was chosen as the main calculation method.

Calculations of relative Gibbs energies of the β -TS[‡] and α -TS[‡] transition states for the two pathways of the first cyclization steps of model compound **1'** (Table 3 in Supplementary data) showed the preferability of nitrogen dioxide reaction with the allyl substituent in compound **1'** having an equatorial configuration (β -orientation of the allyl moiety in **1**) to give intermediate **5'** (Fig. 4). The ratio of the rate constants ($k_{\beta}/k_{\alpha} = 3$, $T = 338$ K) calculated using the Eyring equation and the relative nonequilibrium Gibbs energy ($\Delta\Delta G^{\ddagger}_{\alpha-\beta}$). Hence, based on the data for model compound **1'**, it can be assumed that the formation of four diastereomers **3a–d** with an *R*-configuration of the C-2 spiro atom is preferential in the series of isomeric compounds **3**.

In calculations of the relative Gibbs energies for transition states **6a'–d'** (Table 4 in Supplementary data) that lead to model compounds **3a'–d'**, the relative energies of transition states **6a'–d'** and **6c'–d'** were refined by the G3MP2B3 composite method in accordance with published recommendations.¹⁴ As one can see from Figure 4, transition state **6a'–d'** that leads to isomer **3a'** has the lowest energy barrier. The $\Delta\Delta G^{\ddagger}_{c-a}$ value was found to be 8.1 kJ/mol. The reaction rate ratio $k_a/k_c = 15$ ($T = 338$ K) calculated from this value, that is, the rate constant of cyclization that occurs toward model compound **3a'** or reaction product **3a** is by an order of magnitude higher than the rate constants for the competing pathways. Hence, the experimentally observed formation of *cis*-isomers **3a** and **4a** of spirocyclopentane derivatives of betulonates can be reasonably explained by analyzing data obtained in the framework of theoretical studies, which eliminate the apparent contradiction noted above between the isomerism thermodynamics and NMR data for diastereomeric mixtures of compounds **3** or **4**.

To conclude, we have synthesized hitherto unknown spirocyclic derivatives of lupane terpenoids. Theoretical analysis of the reaction mechanism allowed us to establish the most probable structures of major reaction products **3a** and **4a** that were isolated in individual form from diastereomeric mixtures: methyl 3-oxo-3'-S-(chloromethyl)-4'-R-(nitromethyl)spiro[2(1')R-cyclopentane]-dihydrobetulonate (**3a**) and benzyl 3-oxo-3'-S-(chloromethyl)-4'-R-(nitromethyl)spiro[2(1')R-cyclopentane]-dihydrobetulonate (**4a**).

Acknowledgments

This work was financially supported by the Russian Foundation for Basic Research (Project No. 10_03_00105), the Division of Chemistry and Materials Science of the Russian Academy of Sciences (Program 'Medicinal and Biomolecular Chemistry'), and the Ministry of Education and Science of the Russian Federation (Federal Target Program 'Scientific and Pedagogical Manpower of Innovative Russia' for 2009–2013, State Contract No. 14.740.11.0014).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2011.11.020.

References and notes

- Tolstikov, G. A.; Flekhter, O. B.; Shul'ts, E. E.; Baltina, L. A.; Tolstikov, A. G. *Khimiya v interesakh ustoychivogo razvitiya [Chemistry for Sustained Evolution]* **2005**, *13*, 1 (in Russian).
- Yogeewari, P.; Sriram, D. *Curr. Med. Chem.* **2005**, *12*, 657.
- Mukherjee, R.; Kumar, V.; Srivastava, S. K.; Agarwal, S. K.; Burman, A. C. *Anti-Cancer agents Med. Chem.* **2006**, *6*, 271.
- Urban, M.; Sarek, J.; Klinot, J.; Korinkova, G.; Hajduch, M. *J. Nat. Prod.* **2004**, *67*, 1100.
- Honda, T.; Liby, K. T.; Su, X.; Sundararajan, Ch.; Honda, Y.; Suh, N.; Risingsong, R.; Williams, Ch. R.; Royce, D. B.; Sporn, M. B.; Gribble, G. W. *Bioorg. Med. Chem. Lett* **2006**, *15*, 6306.

- Spivak, A. Yu.; Shakurova, E. R.; Nedopekina, D. A.; Khalitova, R. R.; Khalilov, L. M.; Odinokov, V. N.; Belsky, Y. P.; Ivanova, A. N.; Belska, N. V.; Danilets, M. G.; Ligatcheva, A. A. *Russ. Chem. Bull. Int. Ed.* **2011**, *60*, 694.
- Taniguchi, T.; Ishibashi, H. *Org. Lett.* **2010**, *12*, 124.
- Taniguchi, T.; Goto, N.; Nishibata, A.; Ishibashi, H. *Org. Lett.* **2010**, *12*, 112.
- Yamamoto, Y.; Nakagai, Y.; Ohkoshi, N.; Itoh, K. *J. Am. Chem. Soc.* **2001**, *123*, 6372.
- Okamoto, S.; Livinghouse, T. *Organometallics* **2000**, *19*, 1449.
- Gurjar, M. K.; Ravindranad, S. V.; Sankar, K.; Karmakar, S.; Cherian, J.; Chorghade, M. S. *Org. Biomol. Chem.* **2003**, *1*, 1366.
- Typical procedure*: To a solution of **1** (0.10 g, 0.18 mmol) and FeCl₃ (0.04 g, 0.27 mmol) or LiCl (0.01 g, 0.27 mmol) in THF (3 ml) was added Fe(NO₃)₃·9H₂O (0.09 g, 0.22 mmol), and the mixture was heated at reflux for 3 h. After cooling to room temperature, the resulting suspension was diluted with EtOAc (5 ml) and filtered. After removal of solvent under reduced pressure, the residue was purified by silica gel chromatography (CHCl₃) to give **3** (0.07 g, 65%) as a mixture of diastereomers. Re-chromatography on SiO₂ (hexane:EtOAc, 30→1) separate of **3a** (0.04 g, 60% relative to initial diastereomeric mixture **3**). Methyl 3-oxo-3'-S-(chloromethyl)-4'-R-(nitromethyl)spiro[2(1')R-cyclopentane]-dihydrobetulonate (**3a**): White solid mp = 160–162 °C (EtOH), [α]_D²⁰ + 30.30 (c 1.12, CHCl₃). IR (ν/cm⁻¹): 1760 (C=O). MS, *m/z* 654.98 [M+Na]⁺, 670.96 [M+K]⁺. Anal. Calcd for C₃₇H₅₈ClNO₅: C, 70.28; H, 9.25; Cl, 5.61; N, 2.22. Found: C, 70.03; H, 9.72; Cl, 5.66; N, 2.52. ¹H NMR (400 MHz, CDCl₃): δ 0.71, 0.95, 0.99, 1.10, 1.12 (all s, 3H each, H(25), H(26), H(27), H(24), H(23)), 0.77, 0.88 (both d, *J* = 6.0 Hz, 3H each, H(30), H(29)), 1.18 (m, 1H, H^a(15)), 1.19 (m, 1H, H^a(21)), 1.22 (m, 1H, H^b(12)), 1.24 (m, 1H, H^a(22)), 1.36 (m, 1H, H^a(11)), 1.37 (m, 1H, H^a(16)), 1H, H^b(15); 2H, H(5)), 1.39 (m, 1H, H(18)), 1.43 (m, 2H, H(6)), 1.44 (m, 2H, H(7)), 1.50 (d, ²*J* = 13.0 Hz, 1H, H^a(1)), 1.51 (m, 1H, H^b(11)), 1.56 (m, 1H, H(9)), 1.60 (m, 1H, H^b(5')), 1.73 (m, 1H, H^b(12)), 1H, H^a(2')), 1.82 (m, 1H, H^b(20)), 1H, H^b(21), 1H, H^b(22)), 2.02 (m, 1H, H^b(2')), 2.04 (d, ²*J* = 13.0 Hz, 1H, H^a(1)), 2.24 (m, 1H, H(19)), 2.25 (m, 1H, H^b(16)), 2.27 (m, 1H, H(13)), 2.43 (dd, ²*J* = 13.0 Hz, ³*J* = 8.0 Hz, 1H, H^b(5')), 2.71 (sext, ³*J* = 8.0 Hz, 1H, H(3')), 3.01 (sext, ³*J* = 8.0 Hz, 1H, H(4')), 3.53 (dd, 2H, ²*J* = 14.0 Hz, ³*J* = 7.0 Hz, CH₂Cl), 3.67 (s, 3H, OMe), 4.46, 4.65 (both dd, ²*J* = 13.0 Hz, ³*J* = 8.0 Hz, 2H, CH₂NO₂). ¹³C NMR (100 MHz, CDCl₃): δ 14.53 (C(27)), 14.69 (C(30)), 15.50 (C(26)), 15.75 (C(25)), 20.36 (C(6)), 21.87 (C(11)), 22.56 (C(24)), 22.96 (C(29)), 27.02 (C(12)), 29.58 (C(21)), 29.69 (C(15)), 29.76 (C(20)), 30.25 (C(23)), 32.00 (C(16)), 33.08 (C(7)), 37.28 (C(22)), 37.97 (C(4')), 38.23 (C(13)), 40.46 (C(2)), 40.48 (C(8)), 42.66 (C(14)), 43.13 (C(3')), 44.13 (C(19)), 44.45 (CH₂Cl), 45.00 (C(5')), 45.87 (C(4)), 48.10 (C(2')), 48.36 (C(5)), 48.83 (C(18)), 51.21 (OMe), 51.52 (C(10)), 53.21 (C(9)), 55.93 (C(11)), 56.98 (C(17)), 75.81 (CH₂NO₂), 176.81 (C(28)), 221.23 (C(3)). Benzyl 3-oxo-3'-S-(chloromethyl)-4'-R-(nitromethyl)spiro[2(1')R-cyclopentane]-dihydrobetulonate (**4a**): White solid mp = 120–122 °C (EtOH), [α]_D²⁰ + 37.50 (c 0.08, CHCl₃). IR (ν/cm⁻¹): 1725 (C=O). MS, *m/z* 730.40 [M+Na]⁺, 746.37 [M+K]⁺. Anal. Calcd for C₄₃H₆₂ClNO₅: C, 72.90; H, 8.82; Cl, 5.00; N, 1.98. Found: C, 72.52; H, 8.44; Cl, 5.21; N, 1.89. ¹H NMR (400 MHz, CDCl₃): δ 0.73, 0.93, 0.98, 1.09, 1.12 (all s, 3H each, H(25), H(26), H(27), H(24), H(23)), 0.88, 0.90 (both d, *J* = 6.0 Hz, 3H each, H(30), H(29)), 1.21–2.32 (m, 28H, CH, CH₂ in the betulin residue), 2.43 (dd, ²*J* = 13.0 Hz, ³*J* = 8.0 Hz, 1H, H(5')), 2.71 (sext, ³*J* = 8.0 Hz, 1H, H(3')), 3.01 (sext, ³*J* = 8.0 Hz, 1H, H(4')), 3.52 (dd, ²*J* = 14.0 Hz, ³*J* = 7.0 Hz, 2H, CH₂Cl), 4.46, 4.64 (both dd, ²*J* = 13.0 Hz, ³*J* = 8.0 Hz, 2H, CH₂NO₂), 5.08–5.17 (m, 2H, OCH₂Ph); 7.32–7.37 (m, 10H, Ph). ¹³C NMR (100 MHz, CDCl₃): δ 14.49 (C(27)), 14.68 (C(30)), 15.37 (C(26)), 15.74 (C(25)), 20.35 (C(6)), 21.86 (C(11)), 22.55 (C(24)), 22.96 (C(29)), 27.04 (C(12)), 28.44 (C(21)), 29.46 (C(15)), 29.76 (C(20)), 30.25 (C(23)), 31.95 (C(16)), 33.07 (C(7)), 36.85 (C(22)), 37.26 (C(4')), 37.97 (C(13)), 38.17 (C(2)), 40.46 (C(8)), 42.67 (C(14)), 43.13 (C(3')), 44.13 (C(19)), 44.45 (CH₂Cl), 45.00 (C(5')), 45.86 (C(4)), 48.09 (C(2')), 48.36 (C(5)), 48.82 (C(18)), 51.51 (C(10)), 53.21 (C(9)), 55.93 (C(11)), 56.95 (C(17)), 65.65 (CH₂-Ph), 75.82 (CH₂NO₂), 128.03, 128.28, 128.47, 136.55 (Ph), 175.95 (C(28)), 221.25 (C(3)).
- Conformations of the structures in question were calculated by the B3LYP/6-31G(d) method.^{15–17} In the case of the most stable isomers, the structures were additionally optimized and the vibrational problem was solved in the B3LYP/6-311G(d,p) approximation.¹⁸ Transition states were localized using the B3LYP/6-311G(d,p), BHandHLYP/cc-pVTZ,^{19,20} and G3MP2B3²¹ methods. Energy parameters of the compounds were calculated at 298 K. Nonspecific solvation by the solvent (tetrahydrofuran) was taken into account in the framework of the polarized continuum method²² in the B3LYP/cc-pVTZ approximation. Calculations were performed using Gaussian 09 software, Revision A.01.²³
- Tripp, J. C.; Schiesser, C. H.; Curran, D. P. *J. Am. Chem. Soc.* **2005**, *127*, 5518.
- Becke, A. D. *J. Chem. Phys.* **1993**, *98*, 5648.
- Lee, C.; Yang, W.; Parr, R. G. *Phys. Rev. B.* **1988**, *37*, 785.
- Hariharan, P. C.; Pople, J. A. *Theor. Chem. Acc.* **1973**, *28*, 213.
- Raghavachari, K.; Binkley, J. S.; Seeger, R.; Pople, J. A. *J. Chem. Phys.* **1980**, *72*, 650.
- Becke, A. D. *J. Chem. Phys.* **1993**, *98*, 1372.
- Kendall, R. A.; Dunning, T. H., Jr.; Harrison, R. J. *J. Chem. Phys.* **1992**, *96*, 6796.
- Baboul, A. G.; Curtiss, L. A.; Redfern, P. C.; Raghavachari, K. *J. Chem. Phys.* **1999**, *110*, 7650.
- Cossi, M.; Barone, V.; Cammi, R.; Tomasi, J. *Chem. Phys. Lett.* **1996**, *255*, 327.
- Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, Scalmani, J. R. G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven,

T.; Montgomery, J. A.; Peralta, Jr., J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.;

Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, Revision A.1, Gaussian, Inc., Wallingford CT, 2009.